Co-Diagnostics, Inc. Common Stock (CODX)vsNovartis AG ADR (NVS)
CODX
Co-Diagnostics, Inc. Common Stock
$1.53
-6.13%
HEALTHCARE · Cap: $5.94M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9088881% more annual revenue ($56.58B vs $622,490). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CODX
Hold41
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CODX.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 76.7% year-over-year
Earnings expanding 30.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -125.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CODX
The strongest argument for CODX centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 76.7% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CODX
The primary concerns for CODX are Market Cap, Profit Margin, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
CODX profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
CODX carries more volatility with a beta of 1.43 — expect wider price swings.
CODX is growing revenue faster at 76.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 41/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Co-Diagnostics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?